June 3 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP REPORTS POSITIVE OVERALL RESPONSE RATE IN ITS PHASE II CLINICAL TRIAL IN 1ST LINE NSCLC FOR PD-L1 ALL-COMERS
- IMMUTEP LTD - COMBINATION OF EFTI PLUS PEMBROLIZUMAB SHOWS FAVOURABLE ANTI-TUMOUR ACTIVITY
- IMMUTEP LTD - TACTI-002 HAS MET ITS PRIMARY OBJECTIVE
- IMMUTEP LTD - OTHER SECONDARY ENDPOINTS CONTINUE TO DEMONSTRATE IMPROVEMENT ACROSS ALL PD-L1 EXPRESSION LEVELS
- IMMUTEP LTD - TACTI-002 SAFE AND WELL TOLERATED
- IMMUTEP LTD - EXPECTS TO REPORT FURTHER RESULTS FROM TACTI-002 IN H2 CALENDAR YEAR 2022
News: IMM Immutep Reports Positive Response Rate In Phase II Trial In 1st Line NSCLC For PD-L1...
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.015(3.57%) |
Mkt cap ! $517.1M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.5¢ | 42.0¢ | $1.348M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10725 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 14524 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
43.5¢ |
Change
0.015 ( 3.57 %) |
||||
| Open | High | Low | Volume | ||
| 42.5¢ | 44.0¢ | 42.5¢ | 697373 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| IMM (ASX) Chart |